Evidence map›Paper›PMID 36288499›Full record

ArticleBiomacromolecules2022

Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering.

Pablo Vicente Torres-Ortega, Rubén Del Campo-Montoya, Daniel Plano, Jacobo Paredes, Javier Aldazabal, María-Rosario Luquin, Enrique Santamaría, Carmen Sanmartín, María J Blanco-Prieto, Elisa Garbayo

Open access · hybridAbstract read
In one paragraph

Article in Biomacromolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Pablo Vicente Torres-OrtegaDepartment of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain.
Rubén Del Campo-MontoyaDepartment of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain.ORCID 0000-0001-5314-9130
Daniel PlanoDepartment of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain.
Jacobo ParedesTecnun, School of Engineering, University of Navarra, C/Manuel de Lardizábal 15, 20018San Sebastián, Spain.
Javier AldazabalTecnun, School of Engineering, University of Navarra, C/Manuel de Lardizábal 15, 20018San Sebastián, Spain.
María-Rosario LuquinNavarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008Pamplona, Spain.
Enrique SantamaríaClinical Neuroproteomics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdisNa), 31008Pamplona, Spain.
Carmen SanmartínDepartment of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain.ORCID 0000-0003-3431-7826
María J Blanco-PrietoDepartment of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain.ORCID 0000-0003-0710-899X
Elisa GarbayoDepartment of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008Pamplona, Spain.ORCID 0000-0003-2049-4143
Navarre Institute of Health Research · ESUniversidad de Navarra · ESUniversidad Publica de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The co-administration of glial cell line-derived neurotrophic factor (GDNF) and mesenchymal stem cells (MSCs) in hydrogels (HGs) has emerged as a powerful strategy to enhance the efficient integration of transplanted cells in Parkinson's disease (PD). This strategy could be improved by controlling the cellular microenvironment and biomolecule release and better mimicking the complex properties of the brain tissue. Here, we develop and characterize a drug delivery system for brain repair where MSCs and GDNF are included in a nanoparticle-modified supramolecular guest-host HA HG. In this system, the nanoparticles act as both carriers for the GDNF and active physical crosslinkers of the HG. The multifunctional HG is mechanically compatible with brain tissue and easily injectable. It also protects GDNF from degradation and achieves its controlled release over time. The cytocompatibility studies show that the developed biomaterial provides a friendly environment for MSCs and presents good compatibility with PC12 cells. Finally, using RNA-sequencing (RNA-seq), we investigated how the three-dimensional (3D) environment, provided by the nanostructured HG, impacted the encapsulated cells. The transcriptome analysis supports the beneficial effect of including MSCs in the nanoreinforced HG. An enhancement in the anti-inflammatory effect of MSCs was observed, as well as a differentiation of the MSCs toward a neuron-like cell type. In summary, the suitable strength, excellent self-healing properties, good biocompatibility, and ability to boost MSC regenerative potential make this nanoreinforced HG a good candidate for drug and cell administration to the brain.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsBrainGlial Cell Line-Derived Neurotrophic FactorHydrogelsRatsTissue EngineeringGlial Cell Line-Derived Neurotrophic FactorHydrogels

Identifiers

PMID36288499
PMCPMC9667499
OpenAlexW4307428659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.